Various statements that we make on this website about the company’s future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The terms ‘may,’ ‘will,’ ‘could,’ ‘anticipate,’ ‘plan,’ ‘continue,’ ‘project,’ ‘intend,’ ‘estimate,’ ‘believe,’ ‘expect,’ and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.
In addition, any forward-looking statements represent our views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent the date statements are made.
Princeton, NJ and New York, NY – January 3, 2012 – Ophthotech Corp. announced today that the company will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Samir Patel, M.D., co-founder, president and chief executive officer of Ophthotech, will deliver a presentation on Jan. 11, 2012, at 10:30 a.m. PST in … Read more
– Conference Call and Webcast Today, November 13, at 8:30 a.m. ET – New York, NY, November 13, 2013 – Ophthotech Corporation (Nasdaq: OPHT) today announced financial results for the third quarter and nine months ended September 30, 2013 and provided an update on the Company’s business, and product development programs. Recent Corporate Highlights Ophthotech … Read more
Princeton, NJ – October 24, 2012 – Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech’s FovistaTM anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD) will be presented during Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO) … Read more
Anti-PDGF (1.5 mg) Combination Therapy Resulted in Additional 62% Increase in Visual Outcome Compared to Lucentis® Monotherapy Princeton, NJ – June 13, 2012 – Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis® (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD). In … Read more
Princeton, NJ and New York, NY – January 3, 2013 – Ophthotech Corp. announced today that the company will participate in the 31st Annual J.P. Morgan Healthcare Conference to be held Jan. 7-10, 2013. Samir Patel, M.D., president and chief executive officer of Ophthotech, will deliver a presentation on Mon., Jan. 7 at 2:30 p.m. … Read more
Funding to Develop the First Therapy to Show Superior Efficacy Over the Current Standard of Care Newly Appointed CEO David R. Guyer, MD to Lead Expanded Management Team New York, NY ‒ May 29, 2013 ‒ Ophthotech Corporation today announced that it has raised $175 million to finance a global Phase 3 clinical program of … Read more
New York, NY—August 15, 2013 – Ophthotech Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not … Read more
NEW YORK, NY – September 24, 2013 – Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Ophthotech. In addition, the underwriters have an … Read more
NEW YORK, NY – September 30, 2013 – Ophthotech Corporation today announced the closing of its initial public offering of 8,740,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts, including 1,140,000 shares of common stock issued upon the exercise in full by the underwriters of their option … Read more
NEW YORK, NY – October 30, 2013 – Ophthotech Corporation (Nasdaq: OPHT) today announced that the company will report its financial results for the third quarter ended September 30, 2013 on Wednesday, November 13, 2013 before the U.S. financial markets open. Following the release, Ophthotech management will conduct a conference call to discuss financial results … Read more